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ABSTRACT
Objectives: Core CSF changes in Alzheimer disease (AD) are decreased amyloid 1–42, increased
total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal
degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the
predementia stage, but their diagnostic performance might be affected by age-dependent in-
crease of AD-type brain pathology in cognitively unaffected elderly.
Methods: We investigated effects of age on the diagnostic performance of CSF biomarkers in a
uniquely large multicenter study population, including a cross-sectional cohort of 529 patients
with AD dementia (median age 71, range 43–89 years) and 304 controls (67, 44–91 years), and a
longitudinal cohort of 750 subjects without dementia with mild cognitive impairment (69, 43–89
years) followed for at least 2 years, or until dementia diagnosis.
Results: The specificities for subjects without AD and the areas under the receiver operating
characteristics curves decreased with age. However, the positive predictive value for a combina-
tion of biomarkers remained stable, while the negative predictive value decreased only slightly in
old subjects, as an effect of the high AD prevalence in older ages.
Conclusion: Although the diagnostic accuracies for AD decreased with age, the predictive values
for a combination of biomarkers remained essentially stable. The findings highlight biomarker
variability across ages, but support the use of CSF biomarkers for AD even in older populations.
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GLOSSARY
A42  amyloid 1–42; AD  Alzheimer disease; AUROC  area under the receiver operating characteristic curve; DSM-IV 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition; LR likelihood ratio;MCImild cognitive impairment;NPV
negative predictive value; p-tau  phospho-tau; PPV  positive predictive value; ROC  receiver operating characteristic;
SMCI stablemild cognitive impairment;STARDStandards for the Reporting of Diagnostic Accuracy; t-tau total tau.
Future disease-modifying drugs for Alzheimer disease (AD) will likely be most effective early in
the disease, emphasizing the need for early diagnosis.1 Already before dementia, patients with
AD have reduced CSF amyloid 1–42 (A42), and increased total tau (t-tau) and phosphory-
lated tau (p-tau), probably reflecting plaque pathology, axonal degeneration, and intraneuronal
tangles, respectively.2 Novel diagnostic criteria for AD propose inclusion of in vivo markers of
AD pathology,3,4 thereby enabling diagnosis of patients with mild cognitive impairment (MCI)
and positive biomarkers as prodromal AD3 or MCI due to AD.5 To facilitate this groundbreak-
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ing step, the diagnostic performance of bio-
markers needs to be carefully assessed in
relation to possible confounding factors, such
as age of subjects.
AD-type brain alterations increase with age
in individuals without dementia,6–9 and AD-like
CSF biomarker patterns are reported in about a
third of cognitively unaffected elderly,10–19 but it
is unclear if this reflects asymptomatic AD or if
AD-type brain alterations may be insufficient
for clinical disease with other factors modulating
symptom development. Since most patients
with AD are old, overlap toward healthy sub-
jects might undermine broad-scale use of bio-
markers. To elucidate the impact of age on
biomarker diagnostic performance, we utilized
the largest set of patients with AD with CSF
data to date,13 investigating patients with AD
dementia vs cognitively healthy controls in a
cross-sectional cohort and subjects with MCI in
a longitudinal cohort. We primarily hypothe-
sized that diagnostic accuracies would decrease
with age, but it was unclear how age would af-
fect overall diagnostic usability, since this is also
heavily influenced by disease prevalence.
METHODS Standard protocol approvals and patient
consent. All subjects provided informed consent. Local ethics
committees of the participating centers approved the study.
Subjects. We designed the study following the Standards for
the Reporting of Diagnostic Accuracy (STARD).13,20 The study
population, enrolled at 12 centers in Europe and the United
States between 1990 and 2007, was described previously.13 The
cross-sectional cohort included 529 patients with AD dementia
and 304 cognitively healthy controls, and the longitudinal co-
hort 750 patients with MCI, consecutively recruited at memory
clinics to prospectively evaluate clinically relevant predictive val-
ues. Physicians specialized in cognitive disorders and blinded to
the CSF results assessed all participants. The patients with AD
dementia met dementia criteria defined by DSM-IV and Na-
tional Institute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Disorders Associa-
tion criteria for AD.21,22 As controls we included volunteers with-
out cognitive symptoms (Mini-Mental State Examination 25)
and no active neurologic or psychiatric disease. The patients with
MCI met the revised Petersen criteria at inclusion.23 Exclusion
criteria included known causes of cognitive impairment, such as
brain tumor, subdural hematoma, and ongoing alcohol abuse.
All patients with MCI were followed for a minimum of 2 years,
or until diagnosed with dementia (median follow-up, 3 years;
range, 2–11 years). Some patients with MCI remained cogni-
tively stable (SMCI). Patients with MCI deteriorating to AD
dementia during the study were called MCI-AD (a clinical diag-
nosis of AD dementia defined the reference standard). Patients
with MCI diagnosed with non-AD dementias during the study
were called MCI-other. The requirements of the National Insti-
tute of Neurological Disorders and Stroke–Association Interna-
tionale pour la Recherche en l’Enseignement en Neurosciences
and the criteria established by Roman et al.,24 Erkinjuntti et al.,25
McKeith et al.,26 and Brun et al.27 were used for vascular demen-
tia, dementia with Lewy bodies, and frontotemporal dementia,
respectively. All participants were stratified by age at sampling
into 3 groups: up to 64 years, 65–74 years, and 75 years and
above (table 1; figure e-1, A and B, on the Neurology® Web site
at www.neurology.org). These age limits were chosen pre hoc,
before statistical analyses, and resulted in overall comparable
group sizes. The choice of precisely 3 groups was a tradeoff be-
tween obtaining satisfactorily large groups while still allowing
detection of age-dependent effects.
Variables. The main endpoints were differences in diagnostic
performance for biomarkers between groups. The main predic-
tor was age. Within each age group, we examined the difference
in diagnostic performance between biomarkers.
CSF sampling and biochemical analyses. All CSF proce-
dures have been described previously.13 All participants underwent
lumbar puncture in the L3–4 or L4–5 space. No serious adverse
events were reported. The samples were stored in polypropylene
tubes at80°C or70°C until analysis. Samples were analyzed at
Table 1 Subject counts, sex, MMSE, and prevalence numbers in different
age groups
Cohort and diagnosis
Age groups, ya
<64 65–74 >75 All
Cross-sectional
AD dementia, n (%) 143 (27) 190 (36) 196 (37) 529 (100)
M/F 61/82 71/119 60/136 192/337
MMSEmedian (range) 23 (6–30) 22 (2–30) 22 (7–28) 22 (2–30)
Controls, n (%) 126 (41) 119 (39) 59 (19) 304 (100)
M/F 60/66 57/62 25/34 142/162
MMSEmedian (range) 29 (26–30) 29 (26–30) 29 (26–30) 29 (26–30)
Longitudinal (MCI patients)
All, n (%) 237 (32) 313 (42) 200 (27) 750 (100)
M/F 113/124 150/163 78/122 341/409
MMSEmedian (range) 28 (16–30) 27 (17–30) 26 (18–30) 27 (16–30)
MCI-AD, n (%) 64 (24) 109 (40) 98 (36) 271 (100)
M/F 21/43 42/67 37/61 100/171
MMSEmedian (range) 27 (16–30) 27 (19–30) 26 (18–30) 27 (16–30)
SMCI/MCI-other, n (%)b 173 (36) 204 (43) 102 (21) 479 (100)
M/F 92/181 108/96 41/61 241/238
MMSEmedian (range) 28 (19–30) 27 (17–30) 27 (21–30) 28 (17–30)
Prevalence of MCI subtypes
in age groups, y
64 65–74 75 All
MCI-AD,% 27 35 49 36
SMCI,% 66 58 42 56
MCI-other,% 7 7 9.5 7.9
Abbreviations: AD  Alzheimer disease; MCI  mild cognitive impairment; MMSE  Mini-
Mental State Examination; SMCI stable mild cognitive impairment.
a Data presented as n (% of all in the diagnostic group), number, and MMSE median (range).
b MCI-other included 28 patients with vascular dementia, 14 patients with dementia with
Lewy bodies, 7 patients with frontotemporal lobe dementia, and 10 other deteriorating
non-AD patients, as previously described.13
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the Clinical Neurochemistry Laboratory in Mo¨lndal, Sweden, ex-
cept for samples from Amsterdam, Kuopio, and Munich, where
analyses were done locally. Subsets of samples from these centers
were reanalyzed in Mo¨lndal to adjust for interlaboratory variations
(necessary for A42 and t-tau).13 CSF biomarkers were determined
by ELISA (Innotest®, Innogenetics, Ghent, Belgium).10,13,28,29 For 2
centers, concentrations were determined by Luminex xMAP®
(Inno-Bia AlzBio3®, Innogenetics), and converted to ELISA values
based on previously published conversion factors.30 Experienced and
certified laboratory technicians blinded to all clinical information
performed the analyses.
Statistics. Biomarker distributions. Differences in biomarker
distributions among groups were examined with the nonpara-
metric Kruskal-Wallis test with Dunn post hoc test, correcting
for multiple comparisons. The Spearman correlation coefficient
was used for analyses of correlations between age and biomark-
ers. Statistical significance was set to p  0.05.
Diagnostic accuracy and usefulness. The performance of a
diagnostic test includes its accuracy and usefulness.31 The accu-
racy is the inherent capacity of a test to discriminate disease from
health, affected by the biological variability of the measured fac-
tor between compared groups, and by the technical variability in
the applied procedures. Our principal estimate of diagnostic ac-
curacy was the area under the receiver operating characteristic
curve (AUROC). Receiver operating characteristic (ROC) is a
statistic for the goodness of a predictive test in a binary classifica-
tion task. The ROC curve is a graphic representation of the
sensitivity and specificity of the test across the entire range of
possible classification cutoffs. AUROC 0.50 indicates random
test performance and AUROC 1.00 perfect performance. Sensi-
tivities and specificities were also evaluated at defined cutoffs.
The test usefulness refers to the practical value of the informa-
tion generated by the test, which is affected by factors beyond the
test itself, in particular the disease prevalence. Our measure-
ments of diagnostic usefulness were positive (PPV) and negative
(NPV) predictive values (appendix e-1, “Diagnostic usefulness”),
and positive (LR) and negative (LR) likelihood ratios: LR
sensitivity/(1specificity) and LR (1 sensitivity)/specific-
ity. LRs give useful information if the pretest odds is known,
since a high LR or a small LR changes the post-test odds
significantly from the pretest odds. Most strong tests are charac-
terized by a LR 5 or a LR 0.2.
Comparison of AUROC models. We compared AUROCs
for the same biomarkers across age groups and, since there might
be temporal differences in the development of pathologic traits
in the brains of patients with AD and subjects without AD,
AUROCs for different biomarkers within age groups (appendix
e-1, “Comparison of AUROC models”).
Cutoffs. Sensitivities, specificities, PPVs, NPVs, and LRs
were evaluated at defined cutoffs, generated independent of the
longitudinal cohort, at 85% sensitivity for AD dementia, which
has been suggested as satisfactory for AD biomarkers.32 The cut-
offs applied on the cross-sectional cohort were the specific data
points that yielded at least 85% sensitivity for AD dementia
(appendix e-1, “Cutoffs”), while the cutoffs applied on the longi-
tudinal cohort were linear interpolations at precisely 85% sensi-
tivity. The biomarkers were also combined in a logistic
regression model with the 2 covariates A42/p-tau ratio (Y) and
t-tau (X), used to construct an analytical expression and cutoff
line with 85% sensitivity (Y  3.694  0.0105X, “Combina-
tion”).13 To calculate AUROCs for this combination, the
2-dimensional data were transformed into 1 dimension
(appendix e-1, “Transformation of scatter plot data into 1 di-
mension”). Note that for the cross-sectional cohort, those AU-
ROC estimates must be interpreted with caution, since they will
be biased toward 1 due to a phenomenon called suboptimization
(appendix e-1, “Suboptimization”). From the projected data we
also calculated sensitivity, specificity, LRs, PPV, and NPV for
the combination.
Outliers. Outlying biomarkers were defined as values differ-
ing3 standard deviations from the mean (in each age group of
controls, AD dementia, and MCI). Few subjects exceeded these
limits (appendix e-1, “Outliers”), and excluding them did not
affect the main results (similar AUROC models, and similar re-
sults when comparing AUROCmodels between age groups). No
restrictions were given to outliers in the final analyses.
Software. GraphPad Prism 5 (GraphPad Software Inc., La
Jolla, CA) was used for general statistics. PASW Statistics 18
(SPSS Inc., Chicago, IL) was used for logistic regression analysis.
MedCalc for Windows, version 11.4.4.0 (MedCalc Software,
Mariakerke, Belgium), was used for AUROC modeling and
other estimates of test performance.
RESULTS Biomarker distributions are more similar
between subjects with AD and subjects without AD in
elderly than in young subjects. The biomarker data
have been reported previously,13 but not with de-
tailed studies of accuracy and usefulness in relation to
age. As reported, age correlated with t-tau (r 0.22,
p  0.001) and p-tau (r  0.23, p  0.001) in con-
trols, and with A42 in SMCI (r  0.23, p 
0.001). Since the main aim of the study was to assess
diagnostic performance for MCI-AD toward remain-
ing MCI, we merged SMCI and MCI-other patients.
This was further justified by these groups’ similar
biomarker distributions, except for lower A42 in
the youngest MCI-other patients (figure 1) (the only
bias from this merging is a slight underestimation of
the diagnostic performance for nonprogressive MCI
in the youngest group, since SMCI/MCI-other shifts
toward MCI-AD in A42). All biomarkers differed
across ages, but with different patterns in the differ-
ent diagnostic groups (figure 2, A–F). In sum, older
controls and SMCI/MCI-other had more AD-like
distributions than younger controls and SMCI/MCI-
other, respectively. Likewise, older patients with AD de-
mentia had more control-like A42 and p-tau
distributions than younger patients with AD dementia.
However, as is evident from figure 2, the main source of
variation was diagnosis rather than age.
Diagnostic accuracy for AD decreases with age. We
investigated if the age-dependent variability in bio-
markers affected their diagnostic accuracies for AD
dementia vs controls, and for MCI-AD vs SMCI/
MCI-other. All AUROCs decreased with age (figure
e-1, C–H). AUROCs were also compared within age
groups to determine if the optimal biomarker dif-
fered with age. Generally, the combination of bio-
markers had the highest AUROC and p-tau the
smallest AUROC. We noted that the ROC curves
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for A42 and t-tau intersected in most groups, in a
way that although A42 achieved superior sensitiv-
ity, there were ranges of possible cutoffs where t-tau
had superior specificity.
Specificities for non-AD decrease with age while sensi-
tivities for AD are stable. For all biomarkers, specific-
ities for controls at the 85% sensitivity level
decreased with age (table 2). The combination of
biomarkers had extraordinary specificity in the
youngest controls, and remained superior to any in-
dividual marker in all age groups. In the longitudinal
cohort, specificities for SMCI/MCI-other decreased
with age while sensitivities for MCI-AD were essen-
tially stable (table 2; table e-1).
Likelihood ratios. The LR for the combination of
biomarkers was clearly superior to LR for individ-
ual biomarkers in the youngest subjects, but dropped
close to the level of the LR for A42 in older sub-
jects (table 2). LR increased with age for t-tau and
p-tau, but remained stable (which is preferable) for
A42 and the combination. These results suggest
that the relative extra information from combining
biomarkers compared to using individual biomarkers
is largest to rule in AD in young subjects. LRs in the
longitudinal cohort were closer to 1 than in the cross-
sectional cohort, indicating lower diagnostic useful-
ness, but with the same distribution across ages.
However, from Bayes’ theorem follows that the abso-
lute effect of a diagnostic test depends on disease
prevalence (post-test odds  LR  pretest odds,
where pretest odds is derived from the prevalence),
and as discussed below AD prevalence depended
strongly on age.
Predictive values. The disease probability before a test
is carried out equals the prevalence in the surveyed
group. The PPV is the revised estimate of the same
probability for subjects who are tested positive, and
the NPV is the probability that a negative test is cor-
rect. From this follows that PPV and NPV are pro-
foundly influenced by disease prevalence. PPV is
favored by a high prevalence and NPV is favored by a
low prevalence. In the longitudinal cohort, the prev-
alence of MCI-AD was almost twice as high in the
oldest compared to the youngest group (table 1). In
line with this, PPVs of the individual biomarkers in-
creased with age and NPVs decreased with age (fig-
ure e-1, I–K). At the 85% sensitivity level, the PPV
of the combination of biomarkers was higher than
the PPV of any individual biomarker in all age
groups, while the NPV of the combination of bio-
markers was similar to the NPV of A42 alone in all
age groups (figure 3). For each biomarker and age
group, other cutoffs increased or decreased PPVs with
reversed effects on NPVs (figure 3; figure e-1, I–K).
Figure 1 CSF biomarkers in stable mild cognitive impairment (MCI), MCI-
other, andMCI–Alzheimer disease (AD)
Distribution of biomarkers in the longitudinal cohort (MCI) in different agegroups.Comparisons
between diagnostic groups were done using the nonparametric Kruskal-Wallis test with Dunn
post hoc test, with significant differences indicated as *** (p0.001) and ** (p0.01).
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Figure 2 Comparisons of CSF biomarker distributions in different age groups
Biomarker distributions, presented as cumulative frequencies, in Alzheimer disease (AD) dementia vs controls and stablemild cognitive impairment (SMCI)/
mild cognitive impairment (MCI)-other vsMCI-AD (A–F). An “AD-like” profile is characterized by a left shift of the curves for amyloid 1–42 (A42) and a right
shift for total tau (t-tau)/phospho-tau (p-tau). As explained previously,13 data on CSF A42, t-tau, or p-tau was missing in 19 patients with AD dementia, 1
control, and 1 patient with MCI.
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Influence of APOE genotype. APOE genotype was
available in 189 controls, 400 AD dementia, 223
MCI-AD, and 393 SMCI/MCI-other patients.
APOE 4 had no major effect on correlations be-
tween age and biomarkers (figure e-2).
DISCUSSION Age had distinct effects on the diag-
nostic performance of CSF AD biomarkers. As hy-
pothesized, the specificities for controls and stable
MCI/MCI-other decreased with age. In line with
this, the biomarkers were relatively most useful to
rule in AD in young subjects, in terms of LRs. The
usefulness in absolute terms of a diagnostic test de-
pends on disease prevalence, which increased with
age in this study, causing PPVs to increase or remain
stable (although at modest levels at the predefined
cutoffs), while NPVs dropped slightly in the oldest.
A detailed clarification of age distributions and dis-
ease prevalence is necessary to determine the true di-
agnostic usefulness of a biomarker test. For AD, this
will likely be important for all diagnostic modalities,
including PET amyloid imaging, where measure-
ments correlate tightly with CSF A42.33 Most cut-
offs at 85% sensitivity for AD dementia were similar
across ages, which is in agreement with earlier reports
of CSF biomarker stability during follow-up in
AD.34 Age-adjusted cutoffs are therefore not neces-
sary to retain a low number of false-negative AD
cases, but unadjusted cutoffs will increase the num-
ber of “false-positives” with age, at least with the
follow-up time of this study. At carefully selected
cutoffs, the diagnostic performance of these bio-
markers supports their use in clinical trials for patient
selection or stratification (the high NPVs suggest a
particular usefulness for AD exclusion). If analyzed at
specialized laboratories, minimizing measurement
variability and utilizing reliable reference limits, they
may also aid in dementia investigations.
Similar to other age-related disorders, including
arteriosclerosis, and certain cancer forms (such as
prostate cancer), AD forms a continuum with aging6
which lowers the difference in pathology and diag-
nostic methods between disease and aging with ad-
vanced age. In AD, brain changes likely precede
clinical symptoms by several years. Therefore, a pro-
portion of cognitively intact elderly have preclinical
AD, with an AD-like biomarker profile. This com-
plicates clinical studies on very old patients with AD.
Studies with 10–15 years follow-up may be needed
to fully clarify how to best use biomarkers in the
clinical diagnosis of early-stage AD in the very old.
Our results stress the importance for researchers to
characterize their control populations carefully with
biomarkers, especially in studies of elderly patients.
For clinicians today, the biomarkers’ high NPVs may
be used to exclude AD also in very old patients, while
positive biomarkers may be useful to select patients
for more detailed follow-up. A more daunting per-
spective is that AD-type brain alterations are insuffi-
cient for clinical disease, and that other factors
modulate symptom development.35 Age-dependent
reduced diagnostic accuracies would then be an in-
trinsic problem for biomarkers measuring AD-type
alterations, related to larger questions about AD
pathogenesis. In relation to this, CSF A42 and
p-tau alterations were more pronounced in younger
than in older patients with AD, which contributed to
the age-dependent overlap toward non-AD. More
pronounced differences in younger patients with AD
have been shown previously for CSF A4210 and
other CSF biomarkers, such as ganglioside GM1 and
chromogranin A.36,37 This might reflect a larger het-
erogeneity in older patients with AD, with several
contributing comorbidities.38 Biomarkers for other
pathologies, such as vascular pathology or synucle-
inopathy, might help to clarify this.39–40
A limitation of this study is that clinical rather than
autopsy examination served as the diagnostic standard,
although the reliability of neuropathologic examination
as AD gold standard has been debated.e1 Also, the study
included few very old participants (23 subjects were
85 years), hindering examination of effects of very
Table 2 Specificities and likelihood ratios at cutoffs for 85% sensitivity for
AD dementiaa
Biomarker and
age group, y
Cross-sectional cohort
(AD dementia and controls) Longitudinal cohort (MCI)
Specificity
(controls) LR LR
Specificity
(SMCI/MCI-other) LR LR
A42
<64 82 4.9 0.13 77 3.2 0.33
65–74 82 4.6 0.18 56 1.9 0.28
>75 73 3.2 0.19 60 2.1 0.29
T-tau
<64 74 3.3 0.20 65 2.3 0.29
65–74 53 1.8 0.28 49 1.8 0.19
>75 61 2.2 0.24 46 1.5 0.38
P-tau
<64 67 2.6 0.22 55 1.6 0.48
65–74 46 1.6 0.31 44 1.6 0.23
>75 37 1.4 0.40 30 1.2 0.54
Combination
<64 95 18 0.14 86 5.5 0.27
65–74 83 5.1 0.16 65 2.4 0.21
>75 80 4.3 0.16 61 2.1 0.29
Abbreviations: ADAlzheimer disease; LR likelihood ratio;MCImild cognitive impairment.
a All measurements are calculated at the 85% sensitivity cutoff value for AD dementia.
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high age. In a recent autopsy study, the associations be-
tween dementia and plaque and tangle pathology were
still strong at 75 years, but attenuated at 95 years, so
major effects on the diagnostic performance might ap-
pear first in the oldest old.9 The relatively short
follow-up time in the longitudinal cohort might have
hindered detection of some MCI-AD cases among the
patients with SMCI, underestimating the biomarkers’
true performance if cognitively stable subjects deterio-
rated after the end of the study. The results may also
have been affected by the inclusion of 4 laboratories
(although we tried to normalize for interlaboratory vari-
ability) and by the impact of cognitive reserve (since
years of education for study subjects was not available).
Major strengths of the study include the uniquely large
material, enabling age stratifications with large sub-
groups; the design with independent cutoffs evaluated
in a longitudinal cohort; and the multicenter design
with several participating clinics and laboratories, favor-
ing international generalization of the results.
In the near future, in vivo measurements of AD
pathology in early-stage patients may be included
on a broad scale in clinical and research settings.3,5
To enable this, biomarkers need standardization to
decrease interlaboratory variability,e2,e3 and their
diagnostic performance needs to be carefully de-
termined. Age of study subjects is an important
confounding factor in AD biomarker studies, and
could explain some of the variability in published
diagnostic accuracies and cutoffs. Great care
should be taken to control for age in future stud-
ies. Studies with longer follow-up time may clarify
if effects of age on diagnostic performance are
caused by erroneous classifications of study sub-
jects, or related to yet undeciphered variations in
the biology of neurodegeneration and normal aging.
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